AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03909477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils
Study NCT03909477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.
Study NCT05538455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC4L solutions
Description: Two different versions of the PC4L system will be tested. A fully equipped version and a cloud-based system that requires only a smartphone and a wearable sensor (Fitbit Versa 2). 25% of participants will use the full system, the remaining 75% will use the cloud-based system. As part of the decision support system, the PC4L platform includes a recommendation component. This component collects information from different sources available (directly from sensors, cognitive games, questionnaires, and the multimodal fusion engine), and under clinical and professional guidance, after evaluating the potential improvement or worsening of patients' conditions, issues personalized recommendations to address identified problems. The recommendations relate to the following areas: physical activities; sleep; cognitive; nutrition. These recommendations will generally be sent to the PC4L application on the patients' smartphone, where they will appear as pop-up notifications.
Study NCT05790096 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Granulokine
Description: Granulokine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
Study NCT05790096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastine
Description: Filgrastine is presented in boxes containing vials containing 1,0 mL of solution for injection and 300µg of filgrastim.
Study NCT06225882 — intervention group
Intervention type: DRUG
Intervention: Oxaluria evolution.
Description: To collect real data from the specific French experience by collecting data from patients treated throughout the country and to monitor in particular the evolution of oxaluria before and after treatment.
Study NCT05512130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Description: Participants will take empagliflozin daily for 2 weeks.
Study NCT05512130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will take a placebo daily for 2 weeks. The placebo will be identical to empagliflozin in appearance.
Study NCT05039606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin is a second-generation platinum-like derivative, which is a cell cycle non-specific drug, with a mechanism of action and efficacy similar to cisplatin, and a wide anti-cancer spectrum
Study NCT05039606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug
Study NCT05027529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb
Description: An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit
Study NCT05027529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VA-ECMO only
Description: only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added
Study NCT04274166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg (2 injections per dose
Description: secukinumab 150 mg (2 injections per dose
Study NCT05870241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ga-As Laser
Description: Patient sits on a chair with back support and the two GA-AS laser ( 5 milli Watts \& 904 nm) probe will be applied one on the shoulder tip for 5 minutes and the other application another 5 minutes will be on the center of deltoid muscle. The main power of the laser switch will be turned on. The duration of the treatment will be 10 minutes.
Study NCT04824352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib: 500 mg QD po (BSA ≥ 1.0) or 250 mg QD po (BSA \< 1.0); IE: ifosfamide 1.8 g/m2/d d1-3; etoposide 100 mg/m2/d d1-3 Q2w
Study NCT05039515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60130
Description: Immediate-release capsule containing high dose of the drug substance.
Study NCT05039515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60130
Description: Immediate-release capsule containing low dose of the drug substance.
Study NCT05039515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as powder filled hard capsules
Study NCT05870241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcurrent Electrical Stimulation
Description: The patient sits on a chair with back support and the two electrodes from Microcurrent 850 unit device will be applied one on the shoulder tip and the other electrode on the center of the deltoid muscle. A wet cloth was placed between the electrode and the patient's skin. An adhesive tape was used to hold the electrode over the treated areas. The main power switch will be turned on. The treatment duration will be for 10 minutes.
Study NCT05870241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive traditional physical therapy in the form of manual lymphatic drainage , compression bandage, exercise to increase lymphatic drainage, skin care. and ROM exercises to improve shoulder mobility
Study NCT05870241 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: the patients will receive traditional physical therapy in the form of manual lymphatic drainage , compression bandage, exercise to increase lymphatic drainage, skin care. and ROM exercises to improve shoulder mobility
Study NCT05516004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PXL Platinum 330 system
Description: to determine the efficacy of riboflavin solution and UV light to treat cornea thinning conditions
Study NCT05936671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG-and-ANI-guided anesthesia
Description: During anesthetic maintenance, sevoflurane concentration will be titrated according to EEG monitoring. Sevoflurane concentration will be titrated to maintain intraoperative Patient state index (PSi) ≥ 35 and to avoid burst suppression. Intraoperative target-controlled infusion of remifentanil will be titrated to maintain intraoperative ANI between 50 and 70.
Study NCT05936671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard anesthesia
Description: During anesthetic maintenance, the attending anesthesiologists will provide a routine standard care for anesthetic and analgesic titration. In brief, hemodynamic variables and clinical situations will be used to titrate the sevoflurane concentration and remifentanil infusion rates.
Study NCT05936671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane and remifentanil
Description: For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
Study NCT05936671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and remifentanil
Description: For anesthetic maintenance, balanced anesthesia with sevoflurane inhalation and target controlled infusion of remifentanil will be performed.
Study NCT05936671 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG and ANI
Description: EEG monitoring using SEDline (Masimo, Irvine, California, USA) and Analgesia Nociception Index (ANI; MetroDoloris Medical Systems, Lille, France) monitoring will be performed.
Study NCT06552884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Maternity Identity Development Training)
Description: Monitoring the Effect of the Education Given to Parents According to Maternal Role Ability Theory on Maternal Role Mother-Baby and Father-Infant Attachment
Study NCT06465680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study behavioral change mobile notification
Description: The study's mobile app will be used to deliver push notifications. The notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of five therapeutic approaches: 1) CBT-Behavioral, 2) CBT-Cognitive, 3) Distanced Self-Talk, 4) Mindfulness, 5) Motivational Interviewing.
Study NCT04989725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard arm
Description: Patients on the standard arm will be treated as per standard of care in our institution. Treatment options could include switching to next systemic therapy line, best supportive care or continuing on current systemic therapy.
Study NCT04989725 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: SABR to all oligoprogressive lesions + continuation of current systemic therapy
Study NCT05257798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-β inhibitor treatment
Description: PF-06823859 (IFN-β inhibitor) 100 mg/mL solution for injection
Study NCT05257798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06823859, 0 mg/mL solution for injection
Study NCT04809090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMT
Description: Standard 8 SMT (Stress Management Training) psychological interviews.
Study NCT04809090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMT
Description: Standard 8 SMT (Stress Management Training) psychological interviews.
Study NCT04809090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App CA
Description: An APP together a CA (Conversational Agent).
Study NCT06513559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatomic total shoulder replacement
Description: Humeral head with a metal ball and the glenoid socket with a polyethylene glenoid component.
Study NCT06513559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse total shoulder replacement
Description: Polyethylene socket on the humeral side and the glenosphere going on the glenoid side.
Study NCT06237751 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil 100 MG
Description: Sildenafil 100mg orally half an hour before surgery
Study NCT06404710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants in this group will be given a gradual muscle relaxation exercise.
Study NCT04880694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC3141
Description: To receive continuous infusion of STC3141 at rate 58.3mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care.
Study NCT04880694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC3141
Description: To receive continuous infusion of STC3141 at rate 87.5mg/hr up to 3 days (72hours).~Also to receive appropriate standard of care.
Study NCT05857371 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: lipoaspiration
Description: The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
Study NCT05857371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lipoaspiration
Description: The surgeon will perform lipoaspiration under local anesthesia for the ADSVF production.
Study NCT05857371 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: urethrotomy
Description: The urologist will perform an endoscopic urethrotomy (standard care).
Study NCT05857371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urethrotomy
Description: The urologist will perform an endoscopic urethrotomy (standard care).
Study NCT05857371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous ADSVF administration
Description: ADSVF will be administrated in fibrotic lesion during urethrotomy by the urologist.
Study NCT04940117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eefooton oral solution
Description: Check eGFR value, liver and kidney function every month
Study NCT05774119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breakfast with coffee
Description: breakfast with coffee with 6 mg/caffeine/kg body weight
Study NCT05774119 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: breakfast with water
Description: breakfast with 250 mL of water
Study NCT05074615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranio-Cervical Flexion Training
Description: Participants of this group will receive conventional training along with Cranio-cervical flexion training:~* The pressure cuff is placed behind the neck just next to the occiput and inflated up to a baseline pressure of 20 mmHg. The patient is asked to perform Cranio-Cervical Flexion (CCF) to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the patient is instructed to maintain the contraction for 10 sec for 10 repetitions with brief rest periods between each contraction i.e., 3-5 seconds. Once a set of 10 repetitions of 10 sec is achieved at one target level, the exercise is progressed to train at the next target level up to the final target level at 30 mmHg.~Conventional therapy will be given along with home plan. Exercise protocol will consist of 30 minutes. Exercise will have total 3 sessions/week for 3 weeks.
Study NCT05074615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks
Study NCT05074615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Participants of this group will receive only conventional therapy and home plan will be given which includes;~* Hot pack placed on the posterior neck for 15 minutes.~* Transcutaneous electrical nerve stimulation (TENS) with a frequency of 80 Hz for 20 minutes with 10-30 mA intensity.~* Isometric exercises: Isometric neck flexion, extension, side bending exercises. 10 repetitions. Hold period is 10 seconds for each movement. Resistance would be provided manually by the therapist.~* Stretching exercises: Passive stretching for Sternocleidomastoid, Trapezius, Pectoralis Major. 10 reps and each stretch maintained for 10 seconds.~* Home Plan: Patients will be given a home plan of self-stretches and isometrics and instructions on how to perform and number of repetitions will be guided. Exercise protocol will consist of 25 minutes. Exercise will consist of total 3 sessions/week for 3 weeks
Study NCT06232629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TUS Active
Description: Bilateral GPis will be sonicated using NeuroFUS device for either two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and with 30 W/cm2 Isppa
Study NCT06232629 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TUS Sham
Description: Passive sham: Bilateral GPis will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 0 W/cm2 Isppa~Active sham: Bilateral occipital cortices will be sonicated using NeuroFUS device for two minutes (5Hz protocol) or 40 seconds (10 Hz protocol) per hemisphere and 30 W/cm2 Isppa
Study NCT06388941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: LNP023 administered orally
Study NCT06388941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally
Study NCT06388941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Standard of care
Study NCT06388941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Standard of care
Study NCT05162144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Medial Gastrocnemius Recession
Description: Patients will be operated with PMGR as described by Barouk. No additional procedures will be performed. The surgery will be performed with the patients in a prone position under local anaesthetics. A 3-4 cm transverse skin incision is made in the popliteal fossa, the superficial fascia is opened, and the medial gastrocnemius with its tendon (aponeurosis) is located. The tendon is then cut while lifting it with clamps, and care is taken to cut only the white tendon while sparing the underlying muscle. While performing a dorsiflexion movement of the ankle, careful palpation of the muscle is done to ensure that all tendon strands are cut completely. The incision is closed in layers, and only soft dressings applied. Patients will be instructed to continue the stretching exercises and fully weight-bear from the first postoperative day. If needed, the patients will be allowed to use crutches during the first 2 weeks after surgery. Sutures are removed 2-3 weeks after surgery.
Study NCT05390099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moringa oleifera leaf
Description: Moringa toothpaste
Study NCT05390099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa oleifera leaf
Description: Moringa toothpaste
Study NCT04800016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Vivity Extended Vision IOL
Description: UV and blue-light filtering extended depth of focus foldable IOL intended to provide a full range of vision from distance to functional near.
Study NCT04800016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ Vivity Extended Vision IOL
Study NCT05718817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN1101
Description: XEN1101 capsules
Study NCT05719584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypopressive exercises
Description: patients will receive pelvic floor muscle training with hypopressive exercises at outpatient department. Treatment will continue for 12 weeks 3 days per week. They will receive information about the localization and function of the PFM and transversus abdominis (TrA) muscles. Next, lying in a supine position with flexed knees and hips, they will localize their own pelvic floor with the help of touching their perineum. Then they will be instructed how to contract the PFM correctly, then they will directed to contract PFMs and in the end participants will be taught how to voluntarily contract the PFM simultaneously with diaphragmatic Aspiration(8-10 repetitions daily
Study NCT05719584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle training
Description: patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
Study NCT05719584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: patients will receive only pelvic floor muscle training exercises(pelvic floor muscle contractions) at the outpatient department and treatment will continue for 12 weeks 3 days per week. PFMT will be performed in the lying, sitting and standing positions. The patients will be instructed to perform three sets of 8-12 maximum voluntary contractions held for 6 sec, with 12 sec of rest between each contraction, followed by three fast contractions in a row
Study NCT01443117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV-23 Vaccine
Description: Administered as a 0.5 mL IM dose
Study NCT01443117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-13 Vaccine
Description: Administered as a 0.5 mL IM dose
Study NCT01443117 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Administered as a 0.5 mL IM dose
Study NCT06369922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an Acupuncture mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.